China fines Simcere unit $3.7M for substandard rabies shots

Chinese drug regulators slapped Simcere Pharmaceutical Group's Jiangsu Yanshen unit with a $3.75 million fine for producing substandard human rabies vaccine. Jiangsu Yanshen also will have to foot the bill to re-vaccinate patients at a cost of up to $3.37 million. Report